MRNA Moderna, Inc. - Common Stock
$134,92
Harga · Agu 19, 2026
Fundamental per Jul 31, 2026
Rentang 52M
$22–$141
95% of range
Peringkat Analis
HOLD
30 analysts
Target Harga
$51
P/E (TTM)
-18.7
ROE
-31.3%
Margin Laba Bersih
-145.2%
Tentang Moderna, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
Moderna, Inc adalah sebuah perusahaan farmasi dan bioteknologi yang berkantor pusat di Cambridge, Massachusetts, Amerika Serikat. Perusahaan ini fokus menggunakan teknologi vaksin berdasarkan mRNA. Platform vaksin Moderna memasukkan RNA Duta dengan nukleosida yang termodifikasi (modRNA) sintetis ke sel manusia menggunakan lapisan nanopartikel lipid. mRNA tersebut kemudian memprogram ulang sel untuk memicu respon imun. Moderna mengembangkan vaksin terapeutik mRNA yang dilapisi dengan nanopartikel lipid, menggunakan mRNA dengan nukleosida pseudoridin. Kandidat vaksin dirancang memiliki efisiensi penggandaan dan translasi yang lebih baik melalui mutagenesis insersional.
Baca selengkapnya
Moderna, Inc () adalah sebuah perusahaan farmasi dan bioteknologi yang berkantor pusat di Cambridge, Massachusetts, Amerika Serikat. Perusahaan ini fokus menggunakan teknologi vaksin berdasarkan mRNA. Platform vaksin Moderna memasukkan RNA Duta dengan nukleosida yang termodifikasi (modRNA) sintetis ke sel manusia menggunakan lapisan nanopartikel lipid. mRNA tersebut kemudian memprogram ulang sel untuk memicu respon imun. Moderna mengembangkan vaksin terapeutik mRNA yang dilapisi dengan nanopartikel lipid, menggunakan mRNA dengan nukleosida pseudoridin. Kandidat vaksin dirancang memiliki efisiensi penggandaan dan translasi yang lebih baik melalui mutagenesis insersional.
Saat ini, produk komersial dari Moderna hanya vaksin COVID-19 Moderna. Perusahaan ini memiliki 24 kandidat vaksin, termasuk kandidat vaksin untuk flu musiman, HIV, virus Nipah, dan vaksin COVID-19 kedua yang lebih mudah disimpan dan dikelola daripada vaksin yang ada saat ini. Pada tahun 2020, 65% pendapatan perusahaan ini berasal dari Biomedical Advanced Research and Development Authority dan 24% pendapatan perusahaan ini berasal dari instansi lain di lingkungan pemerintah federal Amerika Serikat.
Sejarah
2010–2016
Pada tahun 2010, ModeRNA Therapeutics dibentuk untuk mengkomersialisasi riset dari ilmuwan sel punca, Derrick Rossi. Rossi terinspirasi dari karya ahli biokimia asal Hungaria, Katalin Karikó mengenai aktivasi imun yang dimediasi RNA. Bersama imunolog asal Amerika, Drew Weissman, Rossi pun menciptakan modifikasi nukleosida yang menekan imunogenisitas dari RNA. Teknologi tersebut kemudian dilisensi dan digunakan oleh Moderna dan BioNTech untuk mengembangkan vaksin COVID-19.
Rossi telah mengembangkan sebuah metode modRNA melalui transfeksi ke sel manusia, kemudian mendediferensiasinya menjadi sel punca sumsum tulang yang lalu didiferensiasi lebih lanjut menjadi tipe sel target yang dituju. Rossi mendekati sesama civitas Universitas Harvard, Timothy A. Springer, yang mengumpulkan investasi dari Kenneth R. Chien, Bob Langer, dan Studio Ventura Flagship Ventures, yang dijalankan oleh Noubar Afeyan. Bersama-sama, mereka mendirikan sebuah perusahaan yang diberi nama sesuai hasil penggabungan dari kata "modified" dan "RNA", yang kebetulan menghasilkan kata "modern".
Pada tahun 2011, Noubar Afeyan, pemegang saham terbesar Moderna, mempekerjakan Stéphane Bancel, yang sebelumnya menjadi pemimpin di BioMérieux dan Eli Lilly and Company, sebagai CEO. Dalam waktu dua tahun sejak didirikan, perusahaan ini telah mencapai valuasi unikorn.
Pada bulan Maret 2013, Moderna dan AstraZeneca menandatangani perjanjian opsi ekslusif selama lima tahun untuk menciptakan, mengembangkan, dan mengkomersialisasikan mRNA untuk pengobatan terapeutik di bidang kardiovaskular, metabolik, penyakit ginjal, dan kanker tertentu. Perjanjian tersebut juga meliputi pembayaran uang muka sebesar $240 juta ke Moderna, dan menjadi "salah satu pembayaran uang muka terbesar dalam sejarah industri farmasi, yang tidak melibatkan obat yang sudah menjalani uji klinis", Hingga May 2020, hanya satu kandidat yang telah melewati uji klinis fase I, yakni pengobatan untuk iskemia miokardium, yang diberi label AZD8601.
Pada bulan September 2013, perusahaan ini diberitakan dapat meningkatkan fungsi jantung di tikus dan meningkatkan harapan hidupnya dengan "mengarahkan diferensiasi [sel punca] mereka ke tipe sel kardiovaskular". Hal tersebut pun menjadi kemajuan signifikan dalam pengobatan regeneratif. Pada bulan Oktober 2013, perusahaan ini mendapat $25 juta dari DARPA untuk mengembangkan terapeutik mRNA. Pada bulan November 2013, perusahaan ini mendapat pendanaan ekuitas sebesar $110 juta.
Pada bulan Januari 2014, Alexion Pharmaceuticals membayar Moderna sebesar $100 juta untuk sepuluh opsi produk, guna mengembangkan pengobatan penyakit langka, termasuk untuk sindrom Crigler-Najjar, menggunakan platform mRNA terapeutik dari Moderna. Walaupun CEO Bancel berharap platform tersebut dapat mulai diuji ke manusia pada tahun 2016, program dengan Alexion tersebut akhirnya dihentikan pada bulan Januari 2017 setelah uji pada hewan menunjukkan bahwa pengobatan Moderna tidak akan cukup aman untuk manusia.
2017 - 2020
Pada bulan November 2017, teknologi mRNA diuji keamanannya oleh Maja Sedic dan koleganya pada tikus Sprague-Dawley dan monyet Cynomolgus di fasilitas milik Charles River Laboratories di Montreal dan Sherbrooke. Mereka menemukan, antara lain, bahwa "mRNA adalah sebuah molekul biologi yang labil sehingga memerlukan penggunaan sistem pengantaran protektif untuk memanfaatkan potensinya secara efektif," karena mRNA menyebar ke luar lokasi penyuntikan sehingga dapat ditemukan di hati, limpa, sumsum tulang, dan jantung.
Pada Januari 2020, Moderna bermitra dengan Institut Nasional Alergi dan Penyakit Menular guna mengembangkan vaksin untuk coronavirus Wuhan.
Catatan
Referensi
Pranala luar
Situs web resmi
Data bisnis Moderna, Inc.:
Sumber: Wikipedia, CC BY-SA 4.0 · Lihat di Wikipedia ↗
MRNA Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$134.92
Kapitalisasi Pasar
$53.56B
P/E (TTM)
-18.7
EPS (TTM)
$-7.26
Pendapatan (TTM)
$1.94B
Imbal Hasil Dividen
—
ROE
-31.3%
D/E Utang/Ekuitas
0.1
Rentang 52M
$22 – $141
MRNA Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Configure
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan & Laba Bersih
$1.94B
2017-12-31
→
2025-12-31
EPS
$-7.26
2019-12-31
→
2025-12-31
Arus Kas Bebas
$-2.06B
2019-12-31
→
2025-12-31
Margin
-145.2%
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Metrik
Tren 5 Tahun
MRNA
Median Rekan
P/E (TTM)
-18.7
16.9
P/S (TTM)
27.6
9.6
P/B
6.2
7.7
EV / EBITDA
-18.0
—
Price / FCF (Harga / FCF)
-25.9
—
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Metrik
Tren 5 Tahun
MRNA
Median Rekan
Operating Margin (Margin Operasi)
-158.1%
—
Net Profit Margin (Margin Laba Bersih)
-145.2%
-36.9%
ROA
-21.3%
-21.8%
ROE
-31.3%
-47.3%
ROIC
-33.9%
—
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Metrik
Tren 5 Tahun
MRNA
Median Rekan
Debt / Equity (Utang / Ekuitas)
0.1
—
Current Ratio (Rasio Lancar)
3.3
3.5
Quick Ratio (Rasio Cepat)
1.4
—
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Metrik
Tren 5 Tahun
MRNA
Median Rekan
Revenue YoY (Pendapatan YoY)
-39.9%
—
Revenue CAGR 3Y (CAGR Pendapatan 3T)
-53.4%
—
Revenue CAGR 5Y (CAGR Pendapatan 5T)
19.3%
—
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Metrik
Tren 5 Tahun
MRNA
Median Rekan
MRNA Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
TAHAN
30 analis
- Beli Kuat 2 6,7%
- Beli 7 23,3%
- Tahan 18 60,0%
- Jual 2 6,7%
- Jual Kuat 1 3,3%
Target Harga 12 Bulan
19 analis · 2026-08-19
Median
$45.00
Rata-rata
$50.84
Di atas semua target →
$134.92
Rendah
$25.00
Tinggi
$79.00
Target median
$45.00
-66,6%
Target rata-rata
$50.84
-62,3%
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
0.77%
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $-1.97 | $-2.12 | 0.15% |
| 31 Maret 2026 | $-3.40 | $-4.04 | 0.64% |
| 31 Des. 2025 | $-2.11 | $-2.70 | 0.59% |
| 30 Sep. 2025 | $-0.51 | $-2.15 | 1.6% |
| 30 Juni 2025 | $-2.13 | $-3.03 | 0.90% |
| 31 Maret 2025 | $-2.52 | $-3.20 | 0.68% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 16
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B | $803M | $60M | $135M | $206M | |
| Cost of Revenue | $868M | $1.46B | $4.69B | $5.42B | $2.62B | $8M | $0 | $0 | · | |
| R&D Expense | $3.13B | $4.54B | $4.84B | $3.29B | $1.99B | $1.37B | $496M | $454M | $410M | |
| SG&A Expense | $1.02B | $1.17B | $1.55B | $1.13B | $567M | $188M | $110M | $94M | $65M | |
| Operating Expenses | $5.02B | $7.18B | $11.09B | $9.84B | $5.17B | $1.57B | $606M | $548M | $475M | |
| Operating Income | $-3.07B | $-3.94B | $-4.24B | $9.42B | $13.30B | $-763M | $-546M | $-413M | $-269M | |
| Interest Income | $314M | $425M | $421M | $200M | $18M | $25M | $39M | $27M | $15M | |
| Other Non-op | $-8M | $-87M | $-124M | $-45M | $-29M | $-6M | $-8M | $2M | $-2M | |
| Pretax Income | $-2.77B | $-3.61B | $-3.94B | $9.57B | $13.29B | $-744M | $-515M | $-384M | $-256M | |
| Income Tax | $54M | $-46M | $772M | $1.21B | $1.08B | $3M | $-1M | $326.0K | $-80.0K | |
| Net Income | $-2.82B | $-3.56B | $-4.71B | $8.36B | $12.20B | $-747M | $-514M | $-385M | $-256M | |
| EPS (Basic) | $-7.26 | $-9.28 | $-12.33 | $21.26 | $30.31 | $-1.96 | $-1.55 | · | · | |
| EPS (Diluted) | $-7.26 | $-9.28 | $-12.33 | $20.12 | $28.29 | $-1.96 | $-1.55 | · | · | |
| Shares (Basic) | 389,000,000 | 384,000,000 | 382,000,000 | 394,000,000 | 403,000,000 | 381,000,000 | 331,000,000 | · | · | |
| Shares (Diluted) | 389,000,000 | 384,000,000 | 382,000,000 | 416,000,000 | 431,000,000 | 381,000,000 | 331,000,000 | · | · | |
| EBITDA | $-2.86B | $-3.76B | $-3.62B | $9.77B | $13.53B | $-732M | $-515M | · | · |
Neraca 28
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.60B | $1.93B | $2.91B | $3.21B | $6.85B | $2.62B | $236M | $658M | $135M | |
| Receivables | $184M | $358M | $892M | $1.39B | $3.17B | $1.39B | $5M | $12M | $12M | |
| Inventory | $153M | $117M | $202M | $949M | $1.44B | $47M | $0 | · | · | |
| Prepaid Expense | $408M | $599M | $627M | $1.20B | $728M | $252M | $19M | $28M | $13M | |
| Other Current Assets | $45M | $58M | $88M | $44M | $26M | $11M | · | · | · | |
| Current Assets | $6.54B | $8.10B | $10.32B | $13.43B | $16.07B | $6.30B | $1.13B | $1.56B | $783M | |
| PP&E (Net) | · | · | · | · | · | · | · | $212M | $139M | |
| PP&E (Gross) | · | · | · | · | · | · | · | $276M | $187M | |
| Accum. Depreciation | · | · | · | · | · | · | · | $64M | $48M | |
| Goodwill | $52M | $52M | $52M | $0 | · | · | · | · | · | |
| Intangibles | $45M | $40M | $44M | $0 | · | · | · | · | · | |
| Other Non-current Assets | $605M | $594M | $766M | $988M | $46M | $2M | $2M | $3M | $5M | |
| Total Assets | $12.34B | $14.14B | $18.43B | $25.86B | $24.67B | $7.34B | $1.59B | $1.96B | $1.08B | |
| Accounts Payable | $317M | $405M | $520M | $487M | $302M | $18M | $7M | $31M | $21M | |
| Accrued Liabilities | $1.39B | $1.43B | $1.80B | $2.10B | $1.47B | $470M | $68M | $79M | $73M | |
| Current Liabilities | $1.99B | $2.21B | $3.02B | $4.92B | $9.13B | $4.39B | $143M | $223M | $191M | |
| Capital Leases | $653M | $671M | $643M | $92M | $106M | $97M | $94M | · | · | |
| Deferred Tax | $249M | $231M | $235M | · | · | · | · | · | · | |
| Other Non-current Liabilities | $285M | $267M | $256M | $135M | $76M | $3M | $138.0K | $258.0K | $2M | |
| Total Liabilities | $3.69B | $3.24B | $4.57B | $6.74B | $10.52B | $4.78B | $415M | $432M | $459M | |
| Total Debt | $590M | · | · | · | · | · | · | · | · | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $34.0K | $33.0K | $6.0K | |
| Paid-in Capital | $1.38B | $866M | $371M | $1.17B | $4.21B | $4.80B | $2.67B | $2.54B | $72M | |
| Retained Earnings | $7.22B | $10.04B | $13.61B | $18.32B | $9.96B | $-2.24B | $-1.50B | $-1.01B | $-622M | |
| AOCI | $45M | $-10M | $-123M | $-370M | $-24M | $3M | $2M | $-1M | $-1M | |
| Stockholders' Equity | $8.65B | $10.90B | $13.85B | $19.12B | $14.14B | $2.56B | $1.18B | $1.53B | $-551M | |
| Liabilities + Equity | $12.34B | $14.14B | $18.43B | $25.86B | $24.67B | $7.34B | $1.59B | $1.96B | $1.08B | |
| Shares Outstanding | 394,000,000 | 386,000,000 | 382,000,000 | 385,000,000 | 403,000,000 | 399,000,000 | 336,536,985 | 328,798,904 | 65,206,999 |
Arus Kas 14
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $211M | $185M | $617M | $348M | $232M | $31M | $31M | $25M | $21M | |
| Stock-based Comp | $483M | $429M | $305M | $226M | $142M | $93M | $81M | $73M | $40M | |
| Deferred Tax | $10M | $-1M | $901M | $-578M | $-296M | $0 | $-1M | $0 | $0 | |
| Other Non-cash | $245M | $-56M | $-227M | $-3.38B | $1.34B | $2.65B | $-56M | · | · | |
| Operating Cash Flow | $-1.87B | $-3.00B | $-3.12B | $4.98B | $13.62B | $2.03B | $-459M | $-331M | $-331M | |
| CapEx | $192M | $1.05B | $707M | $400M | $284M | $68M | $32M | $106M | $58M | |
| Investing Cash Flow | $1.95B | $1.95B | $4.21B | $-5.18B | $-8.52B | $-1.67B | $-15M | $-373M | $417M | |
| Stock Issued | · | · | · | $0 | $0 | $1.85B | $0 | $563M | · | |
| Stock Repurchased | $2M | $0 | $1.15B | $3.33B | $857M | $0 | $0 | · | · | |
| Net Stock Activity | $-2M | $0 | $-1.15B | $-3.33B | $-857M | $1.85B | · | · | · | |
| Financing Cash Flow | $593M | $56M | $-1.38B | $-3.45B | $-873M | $2.03B | $52M | $1.23B | $168.0K | |
| Net Change in Cash | $668M | $-999M | $-289M | $-3.64B | $4.22B | $2.39B | $-422M | $523M | $86M | |
| Taxes Paid | $26M | $197M | $-357M | $2.73B | $480M | $1M | $0 | $294.0K | $398.0K | |
| Free Cash Flow | $-2.06B | $-4.05B | $-3.83B | $4.58B | $13.34B | $1.96B | $-491M | · | · |
Profitabilitas 7
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -158.1% | -121.9% | -61.9% | 48.9% | 72.0% | -95.0% | -906.4% | · | · | |
| Net Margin | -145.2% | -110.0% | -68.8% | 43.4% | 66.1% | -93.0% | -853.7% | · | · | |
| Pretax Margin | -142.4% | -111.5% | -57.6% | 49.7% | 71.9% | -92.7% | -854.9% | · | · | |
| EBITDA Margin | -147.3% | -116.2% | -52.9% | 50.7% | 73.2% | -91.1% | -854.9% | · | · | |
| ROA | -21.3% | -21.9% | -21.3% | 33.1% | 76.2% | -16.7% | -28.5% | · | · | |
| ROE | -31.3% | -31.2% | -34.5% | 45.1% | 100.6% | -28.1% | -42.4% | · | · | |
| ROIC | -33.9% | -35.7% | -36.6% | 43.0% | 86.3% | -29.9% | -46.4% | · | · |
Likuiditas & Solvabilitas 4
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.7 | 3.4 | 2.7 | 1.8 | 1.4 | 7.9 | · | · | |
| Quick Ratio | 1.4 | 1.0 | 1.3 | 0.9 | 1.1 | 0.9 | 1.7 | · | · | |
| Debt / Equity | 0.1 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.1 | · | · | · | · | · | · | · | · |
Efisiensi 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.2 | 0.3 | 0.8 | 1.2 | 0.2 | 0.0 | · | · | |
| Inventory Turnover | 6.4 | 9.2 | 8.2 | 4.5 | 3.5 | 0.3 | · | · | · | |
| Receivables Turnover | 7.2 | 5.2 | 6.0 | 8.4 | 8.1 | 1.2 | 8.6 | · | · |
Tingkat Pertumbuhan 5
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -39.9% | -52.8% | -64.5% | 4.3% | 2200.2% | · | · | · | · | |
| Revenue CAGR 3Y | -53.4% | -44.0% | 104.3% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.3% | · | · | · | · | · | · | · | · | |
| EPS YoY | · | · | · | -28.9% | · | · | · | · | · | |
| Net Income YoY | · | · | · | -31.5% | · | · | · | · | · |
Valuasi (TTM) 14
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B | $803M | $60M | $135M | · | |
| Net Income TTM | $-2.82B | $-3.56B | $-4.71B | $8.36B | $12.20B | $-747M | $-514M | $-385M | · | |
| Market Cap | $11.62B | $16.05B | $37.99B | $69.15B | $102.35B | $41.66B | $6.58B | · | · | |
| Enterprise Value | $9.61B | · | · | · | · | · | · | · | · | |
| P/E | -4.1 | -4.5 | -8.1 | 8.9 | 9.0 | -53.3 | -12.6 | · | · | |
| P/S | 6.0 | 5.0 | 5.5 | 3.6 | 5.5 | 51.9 | 109.7 | · | · | |
| P/B | 1.3 | 1.5 | 2.7 | 3.6 | 7.2 | 16.3 | 5.6 | · | · | |
| P / Tangible Book | 1.4 | 1.5 | 2.8 | 3.6 | 7.2 | 16.3 | · | · | · | |
| P / Cash Flow | -6.2 | -5.3 | -12.2 | 13.9 | 7.5 | 20.6 | -14.3 | · | · | |
| P / FCF | -5.6 | -4.0 | -9.9 | 15.1 | 7.7 | 21.3 | -13.4 | · | · | |
| EV / EBITDA | -3.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -4.7 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 4.9 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -24.6% | -22.3% | -12.4% | 11.2% | 11.1% | -1.9% | -7.9% | · | · |
Laporan Laba Rugi 16
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $145M | $389M | $678M | $1.02B | $142M | $108M | $966M | $1.86B | $241M | $167M | $2.81B | $1.83B | $344M | $1.86B | $5.08B | $3.36B | |
| Cost of Revenue | $93M | $955M | $452M | $207M | $119M | $90M | $739M | $514M | $115M | $96M | $929M | $2.24B | $731M | $792M | $1.92B | $1.10B | |
| R&D Expense | $651M | $649M | $775M | $801M | $700M | $856M | $1.12B | $1.14B | $1.22B | $1.06B | $1.41B | $1.16B | $1.15B | $1.13B | $1.21B | $820M | |
| SG&A Expense | $216M | $173M | $308M | $268M | $230M | $212M | $351M | $281M | $268M | $274M | $470M | $442M | $332M | $305M | $375M | $278M | |
| Operating Expenses | $960M | $1.78B | $1.53B | $1.28B | $1.05B | $1.16B | $2.21B | $1.93B | $1.60B | $1.43B | $2.81B | $3.84B | $2.21B | $2.23B | $3.50B | $2.20B | |
| Operating Income | $-815M | $-1.39B | $-857M | $-260M | $-907M | $-1.05B | $-1.25B | $-70M | $-1.36B | $-1.27B | $6M | $-2.01B | $-1.87B | $-366M | $1.58B | $1.17B | |
| Interest Income | $67M | $72M | $70M | $73M | $81M | $90M | $91M | $103M | $111M | $120M | $103M | $105M | $104M | $109M | $87M | $58M | |
| Other Non-op | $-19M | $-18M | $-12M | $0 | $8M | $-4M | $-29M | $-12M | $-27M | $-19M | $-39M | $-51M | $14M | $-48M | $-12M | $-7M | |
| Pretax Income | $-767M | $-1.33B | $-799M | $-187M | $-818M | $-964M | $-1.18B | $21M | $-1.28B | $-1.17B | $70M | $-1.96B | $-1.75B | $-305M | $1.66B | $1.22B | |
| Income Tax | $15M | $9M | $27M | $13M | $7M | $7M | $-64M | $8M | $0 | $10M | $-147M | $1.67B | $-369M | $-384M | $190M | $174M | |
| Net Income | $-782M | $-1.34B | $-826M | $-200M | $-825M | $-971M | $-1.12B | $13M | $-1.28B | $-1.18B | $217M | $-3.63B | $-1.38B | $79M | $1.47B | $1.04B | |
| EPS (Basic) | $-1.97 | $-3.40 | $-2.10 | $-0.51 | $-2.13 | $-2.52 | $-2.91 | $0.03 | $-3.33 | $-3.07 | $0.62 | $-9.53 | $-3.62 | $0.20 | $3.95 | $2.67 | |
| EPS (Diluted) | $-1.97 | $-3.40 | $-2.10 | $-0.51 | $-2.13 | $-2.52 | $-2.91 | $0.03 | $-3.33 | $-3.07 | $0.63 | $-9.53 | $-3.62 | $0.19 | $3.77 | $2.53 | |
| Shares (Basic) | 398,000,000 | 395,000,000 | -775,000,000 | 390,000,000 | 388,000,000 | 386,000,000 | -767,000,000 | 385,000,000 | 384,000,000 | 382,000,000 | -766,000,000 | 381,000,000 | 381,000,000 | 386,000,000 | -794,000,000 | 390,000,000 | |
| Shares (Diluted) | 398,000,000 | 395,000,000 | -775,000,000 | 390,000,000 | 388,000,000 | 386,000,000 | -781,000,000 | 399,000,000 | 384,000,000 | 382,000,000 | -785,000,000 | 381,000,000 | 381,000,000 | 405,000,000 | -841,000,000 | 412,000,000 | |
| EBITDA | $-759M | $-1.33B | · | $-209M | $-851M | $-1.01B | · | $-19M | $-1.32B | $-1.23B | · | $-1.77B | $-1.78B | $-288M | · | $1.28B |
Neraca 25
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.72B | $1.91B | $2.60B | $1.13B | $1.28B | $1.62B | $1.93B | $1.64B | $2.48B | $2.05B | $2.91B | $2.93B | $3.80B | $3.44B | $3.21B | $3.03B | |
| Receivables | $17M | $71M | $184M | $1.05B | $36M | $78M | $358M | $1.56B | $163M | $137M | · | $1.87B | $232M | $1.11B | · | $2.69B | |
| Inventory | $280M | $146M | $153M | $332M | $240M | $128M | $117M | $412M | $399M | $295M | · | $487M | $715M | $732M | · | $2.08B | |
| Prepaid Expense | $380M | $348M | $408M | $716M | $764M | $585M | $599M | $823M | $611M | $645M | · | $873M | $1.19B | $1.35B | · | $1.18B | |
| Other Current Assets | $42M | $51M | $45M | $56M | $57M | $69M | $58M | $46M | $31M | $68M | · | $96M | $53M | $64M | · | $85M | |
| Current Assets | $5.82B | $5.77B | $6.54B | $6.60B | $6.17B | $6.77B | $8.10B | $9.67B | $9.66B | $9.60B | · | $10.80B | $10.60B | $12.12B | · | $14.30B | |
| Goodwill | $52M | $52M | $52M | $52M | $52M | $52M | $52M | $52M | $52M | $52M | · | $52M | $52M | $52M | · | · | |
| Intangibles | $109M | $116M | $45M | $47M | $48M | $49M | $40M | $41M | $42M | $43M | · | $45M | $46M | $48M | · | · | |
| Other Non-current Assets | $618M | $675M | $605M | $530M | $546M | $556M | $594M | $556M | $641M | $650M | · | $661M | $1.29B | $1.16B | · | $38M | |
| Total Assets | $10.96B | $11.49B | $12.34B | $12.13B | $12.01B | $12.70B | $14.14B | $15.80B | $15.68B | $16.73B | · | $19.45B | $21.88B | $24.12B | · | $26.06B | |
| Accounts Payable | $167M | $161M | $317M | $267M | $175M | $226M | $405M | $373M | $279M | $183M | · | $494M | $310M | $389M | · | $330M | |
| Accrued Liabilities | $1.91B | $1.91B | $1.39B | $1.18B | $987M | $1.00B | $1.43B | $1.38B | $1.33B | $1.40B | · | $2.22B | $1.49B | $1.61B | · | $1.86B | |
| Current Liabilities | $2.53B | $2.40B | $1.99B | $1.68B | $1.57B | $1.60B | $2.21B | $2.20B | $2.36B | $2.38B | · | $4.38B | $3.12B | $3.50B | · | $6.81B | |
| Capital Leases | $638M | $645M | $653M | $660M | $666M | $667M | $671M | $679M | $668M | $637M | · | $697M | $104M | $96M | · | $79M | |
| Deferred Tax | $255M | $253M | $249M | $239M | $237M | $234M | $231M | $241M | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $284M | $283M | $285M | $281M | $276M | $274M | $267M | $276M | $266M | $262M | · | $172M | $173M | $163M | · | $81M | |
| Total Liabilities | $4.20B | $4.08B | $3.69B | $2.81B | $2.61B | $2.64B | $3.24B | $3.88B | $3.97B | $3.91B | · | $6.00B | $4.93B | $5.26B | · | $8.06B | |
| Total Debt | $591M | $590M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Paid-in Capital | $1.64B | $1.50B | $1.38B | $1.25B | $1.13B | $982M | $866M | $751M | $631M | $487M | · | $277M | $193M | $731M | · | $1.49B | |
| Retained Earnings | $5.10B | $5.88B | $7.22B | $8.05B | $8.25B | $9.07B | $10.04B | $11.16B | $11.15B | $12.43B | · | $13.39B | $17.02B | $18.40B | · | $16.86B | |
| AOCI | $19M | $25M | $45M | $27M | $23M | $10M | $-10M | $11M | $-71M | $-101M | · | $-211M | $-263M | $-267M | · | $-351M | |
| Stockholders' Equity | $6.76B | $7.41B | $8.65B | $9.33B | $9.40B | $10.07B | $10.90B | $11.93B | $11.71B | $12.82B | $13.85B | $13.46B | $16.95B | $18.86B | $19.12B | $17.99B | |
| Liabilities + Equity | $10.96B | $11.49B | $12.34B | $12.13B | $12.01B | $12.70B | $14.14B | $15.80B | $15.68B | $16.73B | · | $19.45B | $21.88B | $24.12B | · | $26.06B | |
| Shares Outstanding | 399,000,000 | 397,000,000 | 394,000,000 | 391,000,000 | 389,000,000 | 387,000,000 | 386,000,000 | 385,000,000 | 384,000,000 | 383,000,000 | 382,000,000 | 381,000,000 | 381,000,000 | 384,000,000 | 385,000,000 | 387,000,000 |
Arus Kas 12
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $56M | $56M | $66M | $51M | $56M | $38M | $59M | $51M | $40M | $35M | $203M | $246M | $90M | $78M | $80M | $113M | |
| Stock-based Comp | $120M | $104M | $113M | $125M | $130M | $115M | $104M | $112M | $112M | $101M | $79M | $77M | $74M | $75M | $62M | $70M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-105M | $-97M | |
| Other Non-cash | · | $553M | · | · | · | $-219M | · | · | · | $50M | · | · | · | $-1.46B | · | · | |
| Operating Cash Flow | $-526M | $-630M | $930M | $-847M | $-919M | $-1.04B | $825M | $-1.57B | $-1.27B | $-989M | $622M | $-1.60B | $-915M | $-1.23B | $1.66B | $252M | |
| CapEx | $37M | $62M | $39M | $33M | $3M | $117M | $522M | $151M | $182M | $196M | $220M | $140M | $234M | $113M | $92M | $89M | |
| Investing Cash Flow | $329M | $-76M | $-48M | $700M | $564M | $730M | $-539M | $721M | $1.65B | $118M | $-538M | $789M | $1.94B | $2.01B | $-1.05B | $945M | |
| Stock Repurchased | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $-1M | $628M | $526M | $402M | $1.01B | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-526M | · | · | |
| Financing Cash Flow | $14M | $17M | $581M | $-1M | $9M | $4M | $-3M | $11M | $34M | $14M | $-109M | $-58M | $-668M | $-542M | $-438M | $-1.04B | |
| Net Change in Cash | $-185M | $-688M | $1.46B | $-147M | $-345M | $-303M | $282M | $-833M | $409M | $-857M | $-25M | $-869M | $361M | $244M | $176M | $156M | |
| Free Cash Flow | · | $-692M | · | · | · | $-1.15B | · | · | · | $-1.19B | · | · | · | $-1.34B | · | · |
Profitabilitas 7
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -562.1% | -356.8% | · | -25.6% | -638.7% | -972.2% | · | -3.8% | -565.6% | -758.1% | · | -109.9% | -542.7% | -19.7% | · | 34.7% | |
| Net Margin | -539.3% | -345.2% | · | -19.7% | -581.0% | -899.1% | · | 0.70% | -530.7% | -703.6% | · | -198.2% | -401.2% | 4.2% | · | 31.0% | |
| Pretax Margin | -529.0% | -342.9% | · | -18.4% | -576.1% | -892.6% | · | 1.1% | -530.7% | -697.6% | · | -106.9% | -508.4% | -16.4% | · | 36.2% | |
| EBITDA Margin | -523.4% | -342.4% | · | -20.6% | -599.3% | -937.0% | · | -1.0% | -549.0% | -737.1% | · | -96.5% | -516.6% | -15.5% | · | 38.0% | |
| ROA | -6.8% | -11.1% | · | -1.4% | -6.0% | -6.6% | · | 0.07% | -6.8% | -5.8% | · | -16.0% | -5.8% | 0.31% | · | 4.4% | |
| ROE | -9.7% | -15.4% | · | -1.9% | -7.8% | -8.5% | · | 0.10% | -8.9% | -7.4% | · | -23.1% | -7.9% | 0.44% | · | 7.4% | |
| ROIC | -11.3% | -17.5% | · | -3.0% | -9.7% | -10.5% | · | -0.36% | -11.6% | -10.0% | · | -27.7% | -8.7% | 0.50% | · | 5.5% |
Likuiditas & Solvabilitas 4
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | · | 3.9 | 3.9 | 4.2 | · | 4.4 | 4.1 | 4.0 | · | 2.5 | 3.4 | 3.5 | · | 2.1 | |
| Quick Ratio | 0.7 | 0.8 | · | 1.3 | 0.8 | 1.1 | · | 1.5 | 1.1 | 0.9 | · | 1.1 | 1.3 | 1.3 | · | 0.8 | |
| Debt / Equity | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Efisiensi 3
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.4 | 7.0 | · | 0.6 | 0.4 | 0.4 | · | 1.1 | 0.2 | 0.2 | · | 1.7 | 0.6 | 0.6 | · | 0.7 | |
| Receivables Turnover | 5.5 | 5.2 | · | 0.8 | 1.4 | 1.0 | · | 1.1 | 1.2 | 0.3 | · | 0.8 | 0.2 | 0.9 | · | 1.2 |
Valuasi (TTM) 14
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.69B | $1.66B | · | $3.13B | $2.35B | $2.38B | · | $4.10B | $2.58B | $4.20B | · | $7.40B | $10.32B | $16.04B | · | $19.15B | |
| Net Income TTM | $-3.15B | $-3.34B | · | $-1.98B | $-3.06B | $-3.41B | · | $-6.07B | $-7.46B | $-6.11B | · | $-3.89B | $1.94B | $6.98B | · | $10.23B | |
| Market Cap | $27.94B | $20.17B | · | $10.10B | $10.73B | $10.97B | · | $25.73B | $45.60B | $40.81B | · | $39.35B | $46.29B | $58.97B | · | $45.76B | |
| Enterprise Value | $26.81B | $18.85B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -8.7 | -5.9 | · | -5.0 | -3.5 | -3.2 | · | -4.2 | -6.1 | -6.6 | · | -9.9 | 28.0 | 9.3 | · | 4.9 | |
| P/S | 16.5 | 12.2 | · | 3.2 | 4.6 | 4.6 | · | 6.3 | 17.7 | 9.7 | · | 5.3 | 4.5 | 3.7 | · | 2.4 | |
| P/B | 4.1 | 2.7 | · | 1.1 | 1.1 | 1.1 | · | 2.2 | 3.9 | 3.2 | · | 2.9 | 2.7 | 3.1 | · | 2.5 | |
| P / Tangible Book | 4.2 | 2.8 | · | 1.1 | 1.2 | 1.1 | · | 2.2 | 3.9 | 3.2 | · | 2.9 | 2.7 | 3.1 | · | 2.5 | |
| P / Cash Flow | · | -32.0 | · | · | · | -10.6 | · | · | · | -41.3 | · | · | · | -48.1 | · | · | |
| P / FCF | · | -29.1 | · | · | · | -9.5 | · | · | · | -34.4 | · | · | · | -44.1 | · | · | |
| EV / EBITDA | -35.3 | -14.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | -27.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 15.8 | 11.4 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -11.4% | -16.9% | · | -19.9% | -28.8% | -31.4% | · | -23.8% | -16.5% | -15.0% | · | -10.1% | 3.6% | 10.8% | · | 20.3% |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B |
| Margin Operasi % | -158.1% | -121.9% | -61.9% | 48.9% | 72.0% |
| Laba Bersih | $-2.82B | $-3.56B | $-4.71B | $8.36B | $12.20B |
| EPS Dilusian | $-7.26 | $-9.28 | $-12.33 | $20.12 | $28.29 |
Neraca
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Utang / Ekuitas | 0.1 | — | — | — | — |
| Rasio Lancar | 3.3 | 3.7 | 3.4 | 2.7 | 1.8 |
| Rasio Cepat | 1.4 | 1.0 | 1.3 | 0.9 | 1.1 |
Arus Kas
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $-2.06B | $-4.05B | $-3.83B | $4.58B | $13.34B |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
- Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback?
- Haruskah Anda Beli Moderna Sebelum 5 Agustus?
- Peringatan Saham MRNA: Moderna Naik karena Harapan Vaksin Hantavirus
- Perdagangan Vaksin Kembali? Moderna Menggarap Vaksin Hantavirus Mengirim Saham Naik
- Moderna lampaui perkiraan pendapatan pada kuartal pertama berkat penjualan vaksin COVID yang lebih kuat di pasar internasional
- 3 Perusahaan Membangun Kekayaan Mereka Berdasarkan Vaksin COVID, tetapi Hanya 1 yang Memiliki Rencana Nyata untuk Apa yang Akan Datang
- Aktivitas Opsi Hari Jumat yang Patut Diperhatikan: CRWD, MRNA, KODK
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 905 pengaju · $16.1B total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 154 (-16 vs Kuartal sebelumnya) | 78 (-4 vs Kuartal sebelumnya) | 246 (-9 vs Kuartal sebelumnya) | 274 (+54 vs Kuartal sebelumnya) | -20.1M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| FMR LLC | $2.740.775.945 | 39.137.169 | 17,05% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.625.311.704 | 23.208.792 | 10,11% | Saham |
| Capital World Investors | $1.560.053.964 | 22.276.996 | 9,70% | Saham |
| STATE STREET CORP | $1.101.305.296 | 15.726.193 | 6,85% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.091.159.349 | 15.581.313 | 6,79% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $597.447.261 | 8.548.380 | 3,72% | Saham |
| TWO SIGMA INVESTMENTS, LP | $503.762.906 | 7.193.530 | 3,13% | Saham |
| Flagship Pioneering, LLC | $324.114.597 | 4.628.225 | 2,02% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $306.529.714 | 4.377.120 | 1,91% | Saham |
| JANE STREET GROUP, LLC | $290.778.566 | 4.152.200 | 1,81% | Opsi jual |
| TWO SIGMA ADVISERS, LP | $227.948.853 | 7.729.700 | 1,42% | Saham |
| JANE STREET GROUP, LLC | $214.536.905 | 3.063.500 | 1,33% | Opsi beli |
| CITADEL ADVISORS LLC | $211.924.786 | 3.026.200 | 1,32% | Opsi beli |
| NORGES BANK | $211.915.962 | 3.026.074 | 1,32% | Saham |
| CITADEL ADVISORS LLC | $203.913.354 | 2.911.800 | 1,27% | Opsi jual |
| BANQUE PICTET & CIE SA | $189.039.122 | 2.699.402 | 1,18% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $167.217.424 | 2.387.797 | 1,04% | Saham |
| Merck & Co., Inc. | $161.642.545 | 2.308.190 | 1,01% | Saham |
| BAMCO INC /NY/ | $139.316.702 | 1.989.386 | 0,87% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $139.193.519 | 1.987.627 | 0,87% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $137.687.594 | 1.966.124 | 0,86% | Saham |
| LMR Partners LLP | $136.117.311 | 1.943.700 | 0,85% | Opsi jual |
| Toroso Investments, LLC | $115.364.880 | 3.912.000 | 0,72% | Opsi beli |
| Theleme Partners LLP | $107.960.979 | 1.541.639 | 0,67% | Saham |
| D. E. Shaw & Co., Inc. | $101.368.425 | 1.447.500 | 0,63% | Opsi beli |
| D. E. Shaw & Co., Inc. | $97.565.796 | 1.393.200 | 0,61% | Opsi jual |
| Douglas Lane & Associates, LLC | $94.083.834 | 1.343.479 | 0,59% | Saham |
| BlackRock, Inc. | $84.628.524 | 1.208.461 | 0,53% | Saham |
| GOLDMAN SACHS GROUP INC | $80.055.544 | 1.143.161 | 0,50% | Saham |
| BAILLIE GIFFORD & CO | $74.054.554 | 1.057.469 | 0,46% | Saham |
| PERCEPTIVE ADVISORS LLC | $70.030.000 | 1.000.000 | 0,44% | Opsi jual |
| Allianz Asset Management GmbH | $68.082.956 | 972.197 | 0,42% | Saham |
| Qube Research & Technologies Ltd | $63.536.422 | 907.157 | 0,40% | Saham |
| Amundi | $62.241.193 | 888.779 | 0,39% | Saham |
| VANGUARD GROUP INC | $57.431.598 | 1.947.494 | 0,36% | Saham |
| RHUMBLINE ADVISERS | $56.713.913 | 809.853 | 0,35% | Saham |
| BARCLAYS PLC | $55.557.809 | 793.343 | 0,35% | Saham |
| Lingotto Investment Management LLP | $53.496.407 | 763.907 | 0,33% | Saham |
| Vanguard Global Advisers, LLC | $51.680.249 | 737.973 | 0,32% | Saham |
| LETKO, BROSSEAU & ASSOCIATES INC | $50.759.845 | 724.830 | 0,32% | Saham |
| Telemark Asset Management, LLC | $49.021.000 | 700.000 | 0,30% | Saham |
| Step Capital Management Pte. Ltd. | $48.670.850 | 695.000 | 0,30% | Saham |
| BANK OF AMERICA CORP /DE/ | $48.487.021 | 692.375 | 0,30% | Saham |
| Swiss National Bank | $47.613.397 | 679.900 | 0,30% | Saham |
| Walleye Trading LLC | $42.165.063 | 602.100 | 0,26% | Opsi jual |
| Pictet Asset Management Holding SA | $42.018.569 | 602.512 | 0,26% | Saham |
| Alyeska Investment Group, L.P. | $39.274.155 | 560.819 | 0,24% | Saham |
| Trexquant Investment LP | $35.376.355 | 505.160 | 0,22% | Saham |
| Affinity Asset Advisors, LLC | $35.015.000 | 500.000 | 0,22% | Opsi jual |
| California Public Employees Retirement System | $34.719.894 | 495.786 | 0,22% | Saham |
| OFI INVEST ASSET MANAGEMENT | $33.559.089 | 547.881 | 0,21% | Saham |
| Affinity Asset Advisors, LLC | $33.264.250 | 475.000 | 0,21% | Opsi beli |
| Susquehanna Portfolio Strategies, LLC | $32.987.141 | 471.043 | 0,21% | Saham |
| UBS Group AG | $32.164.779 | 459.300 | 0,20% | Opsi jual |
| Mount Capital Ltd | $32.066.737 | 457.900 | 0,20% | Saham |
| Mitsubishi UFJ Asset Management Co., Ltd. | $31.516.021 | 450.036 | 0,20% | Saham |
| LMR Partners LLP | $30.813.200 | 440.000 | 0,19% | Opsi beli |
| MILLENNIUM MANAGEMENT LLC | $30.716.208 | 438.615 | 0,19% | Saham |
| Ikarian Capital, LLC | $28.012.000 | 400.000 | 0,17% | Opsi jual |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $27.106.792 | 387.074 | 0,17% | Saham |
| Caption Management, LLC | $25.490.920 | 364.000 | 0,16% | Opsi beli |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $25.054.913 | 357.774 | 0,16% | Saham |
| VANGUARD ASSET MANAGEMENT, Ltd | $23.116.133 | 330.089 | 0,14% | Saham |
| Squarepoint Ops LLC | $22.479.630 | 321.000 | 0,14% | Opsi jual |
| TD Asset Management Inc | $22.278.084 | 318.122 | 0,14% | Saham |
| Squarepoint Ops LLC | $21.912.387 | 312.900 | 0,14% | Opsi beli |
| Caption Management, LLC | $21.884.375 | 312.500 | 0,14% | Opsi jual |
| Candriam S.C.A. | $21.632.163 | 309.196 | 0,13% | Saham |
| Alphadyne Asset Management LP | $21.527.222 | 307.400 | 0,13% | Opsi jual |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $21.143.948 | 301.927 | 0,13% | Saham |
| CITIGROUP INC | $21.009.000 | 300.000 | 0,13% | Opsi beli |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $20.685.252 | 407.190 | 0,13% | Saham |
| ALLIANCEBERNSTEIN L.P. | $20.218.654 | 398.005 | 0,13% | Saham |
| CWM, LLC | $19.654.850 | 386.906 | 0,12% | Saham |
| CAPITAL FUND MANAGEMENT S.A. | $19.451.392 | 277.758 | 0,12% | Saham |
| ALGERT GLOBAL LLC | $19.245.645 | 274.820 | 0,12% | Saham |
| Leonteq Securities AG | $18.707.184 | 267.131 | 0,12% | Saham |
| WOLVERINE TRADING, LLC | $17.677.807 | 697.900 | 0,11% | Opsi beli |
| UBS Group AG | $17.173.177 | 245.226 | 0,11% | Opsi beli |
| PLUSTICK MANAGEMENT LLC | $17.157.350 | 245.000 | 0,11% | Saham |
| Legal & General Group Plc | $17.134.800 | 244.678 | 0,11% | Saham |
| Walleye Trading LLC | $16.534.083 | 236.100 | 0,10% | Opsi beli |
| Qube Research & Technologies Ltd | $16.190.936 | 231.200 | 0,10% | Opsi beli |
| UBS Group AG | $15.978.395 | 228.165 | 0,10% | Saham |
| CREDIT AGRICOLE S A | $15.887.986 | 226.874 | 0,10% | Saham |
| Woodline Partners LP | $15.380.969 | 219.634 | 0,10% | Saham |
| Quantinno Capital Management LP | $15.379.041 | 219.606 | 0,10% | Saham |
| CANADA PENSION PLAN INVESTMENT BOARD | $14.972.974 | 213.808 | 0,09% | Saham |
| NEW YORK STATE COMMON RETIREMENT FUND | $14.797.339 | 211.300 | 0,09% | Saham |
| STRS OHIO | $14.697.476 | 209.874 | 0,09% | Saham |
| STATE OF WISCONSIN INVESTMENT BOARD | $14.545.581 | 207.705 | 0,09% | Saham |
| GROUP ONE TRADING LLC | $14.280.167 | 203.915 | 0,09% | Saham |
| Qube Research & Technologies Ltd | $13.662.853 | 195.100 | 0,08% | Opsi jual |
| VAN ECK ASSOCIATES CORP | $13.302.269 | 189.951 | 0,08% | Saham |
| TWIN FOCUS CAPITAL PARTNERS, LLC | $12.997.638 | 185.601 | 0,08% | Saham |
| WOLVERINE TRADING, LLC | $12.948.696 | 511.200 | 0,08% | Opsi jual |
| Jain Global LLC | $12.693.918 | 181.264 | 0,08% | Saham |
| MILLENNIUM MANAGEMENT LLC | $12.206.229 | 174.300 | 0,08% | Opsi jual |
| PRUDENTIAL FINANCIAL INC | $11.814.831 | 168.711 | 0,07% | Saham |
| Chevy Chase Trust Holdings, LLC | $11.556.911 | 165.028 | 0,07% | Saham |
Orang dalam perusahaan 29 orang dalam · 12 pejabat · 14 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| James M Mock | Chief Financial Officer | 2 Juli 2026 M | 66.436 | 0 | 0 | $0 |
| David W Meline | Chief Financial Officer | 9 Agu 2022 M | 2.857 | 0 | 0 | $0 |
| Lorence H. Kim | Chief Financial Officer | 15 Mei 2020 S | 1.219.910 | 0 | 0 | $0 |
| Stephen Hoge | President | 15 Juli 2026 M | 1.483.848 | 0 | 2 | $-6.345.384 |
| Soria Ester Banque | Chief Commercial Officer | 5 Juli 2026 A | — | 0 | 0 | $0 |
| Shannon Thyme Klinger | Chief Legal Officer | 4 Juni 2026 F | 67.468 | 0 | 1 | $-173.550 |
| Arpa Garay | Chief Commercial Officer | 5 Des. 2023 M | 3.690 | 0 | 0 | $0 |
| Juan Andres | Chief Technical Operations and Quality Officer | 28 Des. 2022 M | 12.803 | 0 | 0 | $0 |
| Paul Burton | Chief Medical Officer | 4 Nov. 2022 M | 954 | 0 | 0 | $0 |
| Lori M. Henderson | General Counsel and Secretary | 27 Mei 2021 M | 901 | 0 | 0 | $0 |
| Corinne Le Goff | Chief Commercial Officer | 1 Feb. 2021 A | — | 0 | 0 | $0 |
| Jennifer Ling Lee | Chief Accounting Officer | 9 Maret 2020 S | 4.419 | 0 | 0 | $0 |
| Michael R. Mcdonnell | Direktur | 8 Juli 2026 A | — | 0 | 0 | $0 |
| AFEYAN NOUBAR | Direktur | 21 Mei 2026 M | 3.924 | 0 | 2 | $-1.137.065 |
| David M. Rubenstein | Direktur | 5 Agu 2025 M | 1.527 | 0 | 0 | $0 |
| Abbas Hussain | Direktur | 11 Juni 2025 S | 580 | 0 | 0 | $0 |
| Sandra Horning | Direktur | 30 April 2025 A | 2.352 | 0 | 0 | $0 |
| Elizabeth G Nabel | Direktur | 30 April 2025 A | 3.084 | 0 | 0 | $0 |
| Francois Nader | Direktur | 30 April 2025 A | 20.607 | 0 | 0 | $0 |
| Elizebeth E Tallett | Direktur | 30 April 2025 A | 703 | 0 | 0 | $0 |
| Paul Sagan | Direktur | 30 April 2025 A | 312.027 | 0 | 0 | $0 |
| Stephen Berenson | Direktur | 6 Mei 2024 A | 22.203 | 0 | 0 | $0 |
| Robert Langer | Direktur | 6 Mei 2024 A | 11.467.664 | 0 | 0 | $0 |
| Moncef Slaoui | Direktur | 29 April 2020 A | — | 0 | 0 | $0 |
| Peter Barton Hutt | Direktur | 20 Nov. 2019 M | 3.924 | 0 | 0 | $0 |
| Israel Ruiz | Direktur | 27 Juni 2019 A | 4.559 | 0 | 0 | $0 |
| Edwin M Kania JR | Pemilik 10% | 14 Jan. 2020 S | 23.847 | 0 | 0 | $0 |
| Stephane Bancel | — | 6 Agu 2026 M | 6.440.260 | 0 | 4 | $-28.715.011 |
| Tal Zvi Zaks | — | 30 Juni 2021 M | 0 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 133 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| FIVY · Tidal Trust II | 7,08% | 7.642 NS | 30 April 2026 | N-PORT |
| GNOM · Global X Funds | 3,28% | 38.755 NS | 31 Mei 2026 | N-PORT |
| BBP · ETFis Series Trust I | 2,49% | 32.122 NS | 30 April 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2,11% | 18.282 NS | 31 Mei 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,30% | 15.139 NS | 30 April 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 1,05% | 293.839 NS | 30 April 2026 | N-PORT |
| BIB · ProShares Trust | 0,94% | 14.600 NS | 31 Mei 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,90% | 6.141 NS | 31 Mei 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,77% | 86.741 NS | 30 April 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,68% | 46.782 NS | 30 April 2026 | N-PORT |
| HIBL · Direxion Shares ETF Trust | 0,54% | 9.339 NS | 30 April 2026 | N-PORT |
| SPXD · DBX ETF Trust | 0,46% | 666 NS | 31 Mei 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,41% | 55.196 NS | 30 April 2026 | N-PORT |
| CGGR · Capital Group Growth ETF | 0,39% | 2.018.912 NS | 31 Mei 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,32% | 139.893 NS | 30 April 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,30% | 940.344 NS | 31 Mei 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0,30% | 38.636 NS | 30 April 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,26% | 162.167 NS | 30 April 2026 | N-PORT |
| GINN · Goldman Sachs ETF Trust | 0,25% | 11.129 NS | 31 Mei 2026 | N-PORT |
| RXL · ProShares Trust | 0,24% | 3.623 NS | 31 Mei 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,23% | 6.933 NS | 30 April 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,19% | 16.705 NS | 31 Mei 2026 | N-PORT |
| GSEW · Goldman Sachs ETF Trust | 0,19% | 71.183 NS | 31 Mei 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,16% | 352 NS | 31 Mei 2026 | N-PORT |
| SFGV · EA Series Trust | 0,16% | 38.316 NS | 29 Mei 2026 | N-PORT |
| FNDX · SCHWAB STRATEGIC TRUST | 0,15% | 818.606 NS | 31 Mei 2026 | N-PORT |
| FNDB · SCHWAB STRATEGIC TRUST | 0,14% | 39.358 NS | 31 Mei 2026 | N-PORT |
| FLCV · Federated Hermes ETF Trust | 0,14% | 2.758 NS | 31 Mei 2026 | N-PORT |
| LGDX · Tidal Trust III | 0,08% | 2.459 NS | 30 April 2026 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0,07% | 98.940 NS | 30 April 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,06% | 5.565 NS | 30 April 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,06% | 190.411 NS | 30 April 2026 | N-PORT |
| SCHG · SCHWAB STRATEGIC TRUST | 0,06% | 742.761 NS | 31 Mei 2026 | N-PORT |
| GVUS · Goldman Sachs ETF Trust | 0,05% | 4.411 NS | 31 Mei 2026 | N-PORT |
| FLCC · Federated Hermes ETF Trust | 0,05% | 1.196 NS | 31 Mei 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,05% | 438.902 NS | 30 April 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0,05% | 142.156 NS | 30 April 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0,05% | 2.798 NS | 30 April 2026 | N-PORT |
| QRFT · Exchange Listed Funds Trust | 0,04% | 143 NS | 30 April 2026 | N-PORT |
| SNPE · DBX ETF Trust | 0,04% | 25.627 NS | 29 Mei 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,04% | 95.873 NS | 31 Mei 2026 | N-PORT |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,04% | 4.074 NS | 31 Mei 2026 | N-PORT |
| SPXT · ProShares Trust | 0,04% | 2.328 NS | 31 Mei 2026 | N-PORT |
| EGLE · Global X Funds | 0,04% | 18 NS | 30 April 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,04% | 17.589 NS | 30 April 2026 | N-PORT |
| DSPY · Tema ETF Trust | 0,03% | 6.244 NS | 31 Mei 2026 | N-PORT |
| AVLC · AMERICAN CENTURY ETF TRUST | 0,03% | 8.452 NS | 31 Mei 2026 | N-PORT |
| XTR · Global X Funds | 0,03% | 24 NS | 30 April 2026 | N-PORT |
| TILT · FlexShares Trust | 0,03% | 13.552 NS | 30 April 2026 | N-PORT |
| SPXN · ProShares Trust | 0,03% | 485 NS | 31 Mei 2026 | N-PORT |